Sanofi-Aventis’ Semuloparin To Face Skeptical FDA At ODAC Meeting
12:50 EDT 18 Jun 2012 | Elsevier Business Intelligence
The agency questions the true benefit of the drug in preventing venous thromboembolism in certain cancer patients, even with a more limited population than the sponsor originally asked for.
Original Article: Sanofi-Aventis’ Semuloparin To Face Skeptical FDA At ODAC Meeting
More From BioPortfolio on "Sanofi-Aventis’ Semuloparin To Face Skeptical FDA At ODAC Meeting"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
